Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 20/20 | 0.49 |
| ▸ | METTL14 | Q9HCE5 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965346 | 1.00 | METTL3 (0.49) | METTL3METTL14 | |
| SCHEMBL25976935 | 0.82 | METTL3 (0.55) | METTL3METTL14 | |
| SCHEMBL31519321 | 0.81 | METTL3 (0.49) | METTL3METTL14 | |
| SCHEMBL23481921 | 0.81 | METTL3 (0.56) | METTL3METTL14 | |
| SCHEMBL17433378 | 0.73 | OPRK1 (0.53) | METTL3METTL14 | |
| SCHEMBL24293761 | 0.72 | METTL3 (0.40) | METTL3METTL14 | |
| SCHEMBL24293745 | 0.71 | METTL3 (0.47) | METTL3METTL14 | |
| SCHEMBL29478321 | 0.71 | METTL3 (0.47) | METTL3METTL14 | |
| SCHEMBL23481923 | 0.71 | METTL3 (0.52) | METTL3METTL14 | |
| SCHEMBL9929376 | 0.71 | AHR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| CN-115151540-A | Polyheterocyclic compounds as METTL3 inhibitors | 风暴治疗有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021111124-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | METTL3 1/4885METTL14 8/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | METTL3 1/4885METTL14 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.